Abbott Labs's most recent trend suggests a bearish bias. One trading opportunity on Abbott Labs is a Bear Call Spread using a strike $118.00 short call and a strike $123.00 long call offers a potential 22.55% return on risk over the next 3 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $118.00 by expiration. The full premium credit of $0.92 would be kept by the premium seller. The risk of $4.08 would be incurred if the stock rose above the $123.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Abbott Labs is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Abbott Labs is bearish.
The RSI indicator is at 36.96 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Abbott Labs
Is Abbott Laboratories (ABT) Stock Outpacing Its Medical Peers This Year?
Fri, 12 Mar 2021 16:30:04 +0000
Is (ABT) Outperforming Other Medical Stocks This Year?
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
Thu, 11 Mar 2021 22:45:10 +0000
Abbott (ABT) closed the most recent trading day at $117.52, moving +1.42% from the previous trading session.
Abbott Announces its Pandemic Defense Coalition: A Global Network of Expert Collaborators Designed To Help Prevent Future Pandemics, Currently Searching for COVID-19 Variants
Thu, 11 Mar 2021 14:00:00 +0000
Abbott (NYSE: ABT) today announced the formation of the Abbott Pandemic Defense Coalition, a first-of-its-kind global scientific and public health partnership dedicated to the early detection of, and rapid response to, future pandemic threats. By connecting global centers of excellence in laboratory testing, genetic sequencing and public health research, the program will identify new pathogens, analyze potential risk level, rapidly develop and deploy new diagnostic testing and assess public health impact in real time.
Here's Why You Should Retain AMN Healthcare (AMN) Stock Now
Tue, 09 Mar 2021 16:27:04 +0000
Investor optimism is high on AMN Healthcare (AMN) stock, courtesy of its solid prospects.
Abbott (ABT) Launches Telehealth Tool for Neuromodulation
Tue, 09 Mar 2021 14:16:02 +0000
Abbott (ABT) stated that Medicare will cover remote programming services as a telehealth benefit through the duration of the public health emergency.
Related Posts
Also on Market Tamer…
Follow Us on Facebook